23 February 2021 - Antengene today announced that China's National Medical Products Administration has granted priority review to the new drug ...
22 February 2021 - Innovent Biologics today jointly announce that the Center for Drug Evaluation of China's National Medical Products Administration ...
19 February 2021 - Third sNDA for toripalimab in China. ...
3 February 2021 - Innovent Biologics and Eli Lilly today jointly announced that the National Medical Products Administration of China has ...
3 February 2021 - The Chinese National Medical Products Administration (NMPA) has approved Nubeqa (darolutamide) for the treatment of patients with ...
3 February 2021 - Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings. ...
4 February 2021 - Forxiga is the first SGLT2 inhibitor approved in China for heart failure with reduced ejection fraction in ...
26 January 2021 - Symbicort Turbuhaler becomes the first dual-combination therapy approved in China for mild, moderate and severe asthma ...
13 January 2021 - BeiGene today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products ...
12 January 2021 - Innovent Biologics today announced that the National Medical Products Administration of China has accepted the supplemental ...
28 December 2020 - Zai Lab today announced that Zejula has been included in the updated National Reimbursement Drug List released ...
27 December 2020 - Internally-developed anti-PD-1 antibody tislelizumab and BTK inhibitor Brukinsa (zanubrutinib) are included in the National Reimbursement Drug List ...
29 December 2020 - Junshi Biosciences is pleased to announce that toripalimab has been included in the updated National Reimbursement Drug ...
7 December 2020 - BeiGene today announced that the China NMPA has approved Blincyto (blinatumomab) for injection for the treatment of ...
19 November 2020 - BeiGene today announced that the China NMPA has approved Xgeva (denosumab) for the prevention of skeletal-related events ...